

Zydus receives market authorisation for Morphine Sulfate ER Tablets

Ahmedabad, 1 July 2015

The Zydus group has received the market authorisation from the USFDA to market Morphine Sulfate ER Tablets.

The product used in the treatment of chronic pain or cancer related pain will be manufactured at Neshor Pharmaceuticals (USA) LLC, located at St. Louis, USA.

A subsidiary of Zydus Pharmaceuticals (USA) Inc., Neshor has considerable expertise in niche therapies with development of products barriers, such as controlled release medications and DEA-controlled substances.
